{"prompt": "['MC1752', '40', 'Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. When', 'symptoms improve to Grade 1 or less, steroid taper should be started and continued', 'over no less than 4 weeks. Replacement of appropriate hormones may be required as', 'the steroid dose is tapered.', 'Hepatic', 'For Grade 2 events, monitor liver function tests more frequently until returned to', 'baseline values (consider weekly).', 'Treat with IV or oral corticosteroids (1 to 2mg/kg/day prednisone or equivalent.)', 'Add prophylactic antibiotics for opportunistic infections', 'For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours.', 'When symptoms improve to Grade 1 or less, a steroid taper should be started and', 'continued over no less than 4 weeks.', 'Renal failure or nephritis', 'For Grade 2 events, treat with corticosteroids.', 'For Grade 3-4 events, treat with systemic corticosteroids.', 'When symptoms improve to Grade 1 or less, steroid taper should be started and', 'continued over no less than 4 weeks.', '9.8', 'Management of treatment related enterocolitis', 'In patients with severe enterocolitis, avelumab will be held and treatment with systemic', 'corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day of prednisone or equivalent.', 'When symptoms improve to Grade 1 or less, corticosteroid taper should be started and continued', 'over at least 1 month.', 'In patients with moderate enterocolitis, avelumab should be withheld and antidiarrheal treatment', 'should be started. If symptoms are persistent for more than one week, systemic corticosteroids', 'should be initiated (e.g., 0.5 mg/kg/day of prednisone or equivalent). When symptoms improve to', 'Grade 1 or less, corticosteroid taper should be started and continued over at least 1 month.', '9.9a', 'Concomitant Medications/Vaccinations (Allowed & Prohibited)', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the ongoing trial. If there is a clinical indication for any medication or vaccination', 'specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be', 'required. The final decision on any supportive therapy or vaccination rests with the investigator', \"and/or the patient's primary treating provider.\", '9.91', 'Acceptable Concomitant Medications', \"All treatments that the investigator considers necessary for a subject's welfare may be\", 'administered at the discretion of the investigator in keeping with the community', 'standards of medical care. All concomitant medication will be recorded in the case report', 'forms (CRF) including all prescription, over-the-counter (OTC), herbal supplements, and', 'IV medications and fluids. If changes occur during the trial period, documentation of', 'drug dosage, frequency, route, and date may also be included on the CRF.', 'All concomitant medications received within 28 days before the first dose of trial', 'treatment and 30 days after the last dose of trial treatment should be recorded.', 'Concomitant medications administered 30 days after the last dose of trial treatment', 'should be recorded for SAEs and ECIs as defined in Section 10.', '9.92', 'Prohibited Concomitant Medications', 'Protocol Version Date: 21JUN2018']['MC1752', '41', 'The following medications are not permitted during the screening and treatment phase', '(including retreatment for post-complete response relapse) of this trial:', 'Anti-neoplastic systemic cytotoxic chemotherapy or biological therapy outside the', 'clinical trial program', 'Immunotherapy not specified in this protocol', 'Chemotherapy not specified in this protocol', 'Investigational agents other than avelumab', 'Live vaccines within 30 days prior to the first dose of trial treatment and while', 'participating in the trial. Examples of live vaccines include, but are not limited to, the', 'following: measles, mumps, rubella, varicella/zoster, yellow fever, intranasal', 'influenza, rabies, BCG, and typhoid vaccine.', 'Systemic glucocorticoids for any purpose other than to modulate symptoms from an', 'event of clinical interest of suspected immunologic etiology. The use of physiologic', 'doses of corticosteroids may be approved after consultation with the principal', 'investigator.', 'NOTE: Use of steroids during chemoradiation for controlling chemotherapy-associated', 'is allowed. We recommend only using up to 4mg dexamethasone weekly.', 'Patients who, in the assessment by the investigator, require the use of any of the', 'aforementioned treatments for clinical management should be removed from the trial.', 'Patients may receive other medications that the investigator deems to be medically', 'necessary.', 'The Exclusion Criteria describes other medications which are prohibited in this trial.', 'There are no prohibited therapies during the Post-Treatment Follow-up Phase.', '9.9b', 'Contraception', 'Avelumab may have adverse effects on a fetus in utero. Furthermore, it is not known if avelumab', 'has transient adverse effects on the composition of sperm.', 'For this trial, male patients will be considered to be of non-reproductive potential if they have', 'azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).', 'Female patients will be considered of non-reproductive potential if they are either:', '(1) postmenopausal (defined as at least 12 months with no menses without an alternative medical', 'cause; in women <45 years of age a high follicle stimulating hormone (FSH) level in the', 'postmenopausal range may be used to confirm a post-menopausal state in women not using', 'hormonal contraception or hormonal replacement therapy. In the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.);', 'OR', '(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral', 'tubal ligation/occlusion, at least 6 weeks prior to screening;', 'OR', '(3) has a congenital or acquired condition that prevents childbearing.', 'Female and male patients of reproductive potential must agree to avoid becoming pregnant or', 'impregnating a partner, respectively, while receiving study drug and for 120 days after the last', 'dose of study drug by complying with one of the following:', '(1) practice abstinence from heterosexual activity;', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}